UT San Antonio
UT Health San Antonio
210-567-7000 Give
Category ID
171

Pheo Para Alliance recognizes UT Health San Antonio as rare disease Center of Excellence

<p>Pheo Para Alliance, a patient advocacy organization dedicated to supporting those with pheochromocytoma (pheo) and paraganglioma (para), a rare neuroendocrine tumor, has designated The University of Texas Health Science Center at San Antonio (UT Health San Antonio) as a Pheo Para Center of Excellence. The Center of Excellence Program recognizes institutions worldwide for providing cutting-edge, quality, multidisciplinary care and [&hellip;]</p>

Share This Story

New Surgical Clinical Trial Recruiting Women with BRCA1 Mutations at High Risk for Ovarian Cancer

<p>A New Ovarian Cancer Clinical Trial at UT Health San Antonio MD Anderson Cancer Center is Investigating Efficacy of Surgical Pathways for Women Harboring High-Risk BRCA1 Genetic Mutations Women harboring mutations in the BRCA1 gene face an incredibly high risk of developing ovarian cancer during their lifetime and much higher risks for peritoneal cancer and [&hellip;]</p>

Share This Story

Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability

<p>ERX-41, developed by UT Health San Antonio scientists, exploits a previously unrecognized weakness in breast cancer and other solid tumors. Media contact: Will Sansom, 210-567-2579, Sansom@uthscsa.edu SAN ANTONIO (June 2, 2022) – A compound, developed by a team including scientists from The University of Texas Health Science Center at San Antonio, kills a range of hard-to-treat cancer [&hellip;]</p>

Share This Story

Brian Fricke, MD, shares 6 Steps to Starting Exercise After Cancer Treatment

<p>In honor of cancer survivor’s month, I thought I would share some tips about getting back to exercise after cancer treatment. I also would encourage anyone battling cancer to read these tips, as early research suggests that physical activity during cancer treatment may improve symptoms related to cancer and its treatment. It may also enhance recovery [&hellip;]</p>

Share This Story

Mays Cancer Center has large presence at ASCO Annual Meeting

<p>Investigators from the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer, are presenting multiple research abstracts at this week’s Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Topics and links to abstracts are below. Congratulations to all Mays Cancer Center researchers for this fine work. Impact of [&hellip;]</p>

Share This Story

Oral pill improves care of patients with bone marrow cancer: Study

<p>Results of MOMENTUM myelofibrosis clinical trial presented at ASCO 2022 Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu CHICAGO AND SAN ANTONIO (June 7, 2022) — Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7. Ruben Mesa, MD, FACP, [&hellip;]</p>

Share This Story

Healio: Momelotinib superior to danzol in symptomatic and anemic myelofibrosis

<p>Dr. Ruben Mesa, Mays Cancer Center, is quoted in this article. &nbsp; Read More</p>

Share This Story

Mays Cancer Center receives grants, continued support from American Cancer Society

<p>Contact: Eileen Teves, 210-450-7239, tevese@uthscsa.edu SAN ANTONIO (June 13, 2022) – In late April, American Cancer Society (ACS) awarded the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, two check donations in the amounts of $480,000 for an institutional research grant and $65,000 for cancer support grants. Both checks were [&hellip;]</p>

Share This Story

ASCO Post: Momelotinib for Symptomatic and Anemic Patients With Myelofibrosis

<p>Dr. Ruben Mesa, Mays Cancer Center, is quoted in this article. &nbsp; Read More</p>

Share This Story

San Antonio Business Journal: The new cancer quest and what it means for San Antonio

<p>Drs. Ruben Mesa, Kate Lathrop and Mark Bonnen of the Mays Cancer Center took part in a panel discussion for this story. &nbsp; Read More</p>

Share This Story

Subscribe to Cancer